[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 3 of about 3
1. Smith AE, Pinkney M, Piggott NH, Calvert H, Milton ID, Lunec J: A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues. Hybridoma (Larchmt); 2007 Oct;26(5):281-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Folate biochemical pathway components such as FR-alpha are determinants of response to novel antifolate drugs such as pemetrexed.
  • In spite of its importance in the diagnosis and treatment of cancer, monoclonal antibodies to FR-alpha suitable for immunohistochemical analysis of formalin-fixed and paraffin-embedded biopsy samples, or that can be used for Western blot analysis, are not available.
  • Immunohistochemical analysis of FR-alpha using hybridoma clone BN3.2 in a panel of normal tissues demonstrated expression limited to ovarian epithelia, placental trophoblasts, and proximal kidney tubules.
  • Analysis of a panel of malignant and benign tissues demonstrated limited expression with variable intensities of staining and patterns of both membrane and cytoplasmic reactivity observed between cases.
  • This preliminary study also supports its use in immunohistochemical studies to determine the role of FR-alpha as a tumor prognostic marker and a possible therapeutic target.
  • [MeSH-major] Antibodies, Monoclonal. Carrier Proteins / analysis. Carrier Proteins / immunology. Paraffin Embedding. Receptors, Cell Surface / analysis. Receptors, Cell Surface / immunology
  • [MeSH-minor] Animals. Cell Line. Female. Folate Receptors, GPI-Anchored. Humans. Mice. Mice, Inbred BALB C. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979543.001).
  • [ISSN] 1554-0014
  • [Journal-full-title] Hybridoma (2005)
  • [ISO-abbreviation] Hybridoma (Larchmt)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Carrier Proteins; 0 / Folate Receptors, GPI-Anchored; 0 / Receptors, Cell Surface
  •  go-up   go-down


2. Yu CH, Hwang DN, Yhee JY, Kim JH, Im KS, Nho WG, Lyoo YS, Sur JH: Comparative immunohistochemical characterization of canine seminomas and Sertoli cell tumors. J Vet Sci; 2009 Mar;10(1):1-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, tumor markers are not well-known in veterinary medicine.
  • We sought to determine using immunohistochemistry whether the combined human testicular tumor markers (placental alkaline phosphatase, OCT3/4, CD30, alpha-fetoprotein, inhibin-alpha, vimentin, c-KIT, and desmin) are expressed in canine seminomas and Sertoli cell tumors (SCTs).
  • The results of this study demonstrate differences and similarities between tumor marker expression of testicular tumors in dogs and humans.
  • All the main markers in current routine use are discussed as well as potential useful markers for benign and malignant tumors, and tumor progression.
  • [MeSH-major] Dog Diseases / pathology. Immunohistochemistry / veterinary. Seminoma / veterinary. Sertoli Cell Tumor / veterinary
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Dogs. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Reprod Fertil Dev. 1998;10(7-8):551-5 [10612460.001]
  • [Cites] J Vet Med Sci. 2007 Dec;69(12):1259-62 [18176022.001]
  • [Cites] Mol Hum Reprod. 2000 Nov;6(11):999-1004 [11044462.001]
  • [Cites] Reproduction. 2001 Feb;121(2):287-96 [11226053.001]
  • [Cites] Vet Pathol. 2001 Nov;38(6):661-6 [11732800.001]
  • [Cites] J Histochem Cytochem. 2002 Feb;50(2):283-5 [11799147.001]
  • [Cites] Histopathology. 2002 Aug;41(2):110-7 [12147087.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):935-40 [15223965.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1341-6 [15371950.001]
  • [Cites] Cancer. 2004 Nov 1;101(9):2006-10 [15386301.001]
  • [Cites] Acta Pathol Microbiol Immunol Scand A. 1983 May;91(3):165-76 [6190350.001]
  • [Cites] Prog Clin Biol Res. 1985;203:1-34 [3008176.001]
  • [Cites] J Endocrinol. 1990 Nov;127(2):235-42 [2123496.001]
  • [Cites] J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):863-6 [2285598.001]
  • [Cites] J Comp Pathol. 1994 Apr;110(3):267-73 [8040391.001]
  • [Cites] J Pathol. 1995 Nov;177(3):253-8 [8551387.001]
  • [Cites] Br J Urol. 1996 Jan;77(1):138-42 [8653285.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):615-9 [9591732.001]
  • [Cites] Mol Hum Reprod. 1999 Sep;5(9):851-60 [10460224.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):289-96 [16188233.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2005 Nov;34(11):711-5 [16536313.001]
  • [Cites] Hum Pathol. 2006 Jun;37(6):662-7 [16733205.001]
  • [Cites] Histopathology. 2006 Sep;49(3):290-7 [16918976.001]
  • [Cites] Anal Quant Cytol Histol. 2006 Aug;28(4):181-7 [16927637.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):320-5 [17277761.001]
  • [Cites] Vet Pathol. 2007 May;44(3):394-7 [17491086.001]
  • [Cites] Anticancer Res. 2007 May-Jun;27(3B):1685-8 [17595797.001]
  • [Cites] J Comp Pathol. 2007 Jul;137(1):41-6 [17629966.001]
  • [Cites] Int J Androl. 2007 Aug;30(4):192-7 [17705803.001]
  • [Cites] Vet Pathol. 2007 Nov;44(6):936-43 [18039910.001]
  • [Cites] Hum Pathol. 2000 Sep;31(9):1055-61 [11014571.001]
  • (PMID = 19255517.001).
  • [ISSN] 1229-845X
  • [Journal-full-title] Journal of veterinary science
  • [ISO-abbreviation] J. Vet. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2801099
  •  go-up   go-down


Advertisement
3. Ohmaru T, Yamakawa H, Netsu S, Nokubi M, Konno R: Placental site trophoblastic tumor (PSTT) with multiple metastases and extremely poor prognosis. Int J Clin Oncol; 2009 Oct;14(5):452-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental site trophoblastic tumor (PSTT) with multiple metastases and extremely poor prognosis.
  • Placental site trophoblastic tumor (PSTT) is a rare type of gestational trophoblastic disease.
  • There is a wide clinical spectrum of presentation and behavior ranging from a benign condition to an aggressive disease with a fatal outcome.
  • The mitotic count of the tumor cells was quite high (23/10 high-power fields).
  • It would have been difficult to remove the tumor by surgery because of the tumor size and its invasion, so we suggested chemotherapy.
  • During the sixth cycle of EMA/CO, the disease became drug-resistant and she died 8 months after the first symptom.
  • [MeSH-major] Trophoblastic Tumor, Placental Site / secondary. Uterine Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy. Cell Differentiation. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Drug Resistance, Neoplasm. Etoposide / administration & dosage. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Methotrexate / administration & dosage. Mitotic Index. Neoplasm Invasiveness. Pregnancy. Tomography, X-Ray Computed. Treatment Failure. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1999 May;73(2):216-22 [10329037.001]
  • [Cites] Gynecol Oncol. 1988 Sep;31(1):32-42 [2842238.001]
  • [Cites] Eur J Gynaecol Oncol. 1995;16(4):290-5 [7556286.001]
  • [Cites] Am J Surg Pathol. 1981 Jan;5(1):75-6 [6264815.001]
  • [Cites] Gynecol Oncol. 2006 Mar;100(3):511-20 [16246400.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):415-9 [11520134.001]
  • [Cites] Obstet Gynecol Surv. 2003 Jul;58(7):484-8 [12832940.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):603-7 [16085293.001]
  • [Cites] Gynecol Oncol. 1981 Oct;12(2 Pt 1):238-48 [6271654.001]
  • [Cites] Gynecol Oncol. 1998 Jan;68(1):62-5 [9454662.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):258-62 [17291263.001]
  • [Cites] Placenta. 1984 Jul-Aug;5(4):349-69 [6209706.001]
  • [Cites] J Reprod Med. 2002 Jun;47(6):460-4 [12092014.001]
  • [Cites] Cancer. 1976 Sep;38(3):1214-26 [182351.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):550-3 [15099979.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):164-9 [10502447.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):854-9 [10673528.001]
  • (PMID = 19856056.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; EMA-CO protocol
  •  go-up   go-down






Advertisement